LY294002

For research use only.

Catalog No.S1105 Synonyms: SF 1101, NSC 697286

1379 publications

LY294002 Chemical Structure

CAS No. 154447-36-6

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.

Selleck's LY294002 has been cited by 1379 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
Targets
CK2 [5]
(Cell-free assay)
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
DNA-PK [6]
(Cell-free)
98 nM 0.5 μM 0.57 μM 0.97 μM 1.4 μM
In vitro

LY294002 is not exclusively selective for the PI3Ks, and could in fact act on other lipid kinases and additional apparently unrelated proteins. LY294002 is shown to inhibit not only mTOR and DNA-PK, but also other protein kinases, such as CK2 (casein kinase 2) and Pim-1[5]. LY294002 inactivates Akt/PKB, consequently inhibiting cell proliferation and inducing apoptosis. LY294002 demonstrates a remarkable growth-inhibitory and apoptosis-inducing effect in these colon cancer cell lines, with decreased expression of phosphorylated Akt (Ser473). [2]LY294002 induces marked nuclear pyknosis and diminished cytoplasmic volume in the tumor cells. Thus, LY294002 markedly inhibits ovarian cancer cell proliferation in vitro. LY294002 induces specific G1 arrest in cell growth, leading to almost complete inhibition of melanoma cell proliferation and partial inhibition of MG-63 (osteosarcoma cell line) proliferation. The effect of LY294002 on cell cycle progression may provide insights into a possible link between the PI3K activation pathway and cancer cell cycle regulation. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Sf9 cells NGrvd4xHfW6ldHnvckBie3OjeR?= NG\yeWJKdmirYnn0bY9vKG:oIFjpd{11[WepZXSgZo93cW6nIGDJN2sh\XiycnXzd4VlKGmwIGPmPUBk\WyuczygTWM2OD1zMDFOwG0v MonUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB7OUizOVEoRjFyOUm4N|UyRC:jPh?=
HeLa cells MVrCbY5lcW6pIHHm[olvcXS7IHHzd4F6 NVHETHVMSmmwZHnu[{Bi\m[rbnn0fUBnd3JiUFmzMYtqdmG|ZTDpd49t[XSnZDDmdo9uKEinTHGgZ4VtdHNuIFvpQVYh|ryP MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTZ3OEi3NEc,OTV4NUi4O|A9N2F-
HeLa cells MWrGeY5kfGmxbjDhd5NigQ>? MkT3TY5pcWKrdHnvckBw\iCvVF;SJJBzd3SnaX6gbZNwdGG2ZXSg[pJwdSCKZVzhJINmdGy|LDDJR|UxRTJwNTFOwG0v MmnnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV4NUi4O|AoRjF3NkW4PFcxRC:jPh?=
HeLa (human carcinoma) cells. NHzhRYZHfW6ldHnvckBie3OjeR?= NGDUPG5KdiC4aYTyc{BqdmirYnn0bY9vKG:oIFTORU1l\XCnbnTlcpQheHKxdHXpckBscW6jc3WoSG5CNVCNKTDmdo9uKEinTHGgLIh2dWGwIHPhdoNqdm:vYTmgZ4VtdHNuIFnDOVA:OS52IN88UU4> M1j6U|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkW4PFcxLz5zNU[1PFg4ODxxYU6=
human PC3 cells MWXQdo9tcW[ncnH0bY9vKGG|c3H5 MV2yOUDPxE1? MVWxNlAhcA>? NVXxVIRZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZZQhOjVidV2gZYZ1\XJiMUKwJIhzeyCkeTDNWHQh[XO|YYmgdoVt[XSrdnWgeI8hTE2VTx?= NUnvRVR7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[2PFAyPTlpPkG2OlgxOTV7PD;hQi=>
human BJ cells M3jJTmZ2dmO2aX;uJIF{e2G7 NXLFNnhTOjVizszN NH73cZIzKGh? MkDiRYN1cX[jdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHH0JHRpejNyODDpckBRTEeILYP0bY12dGG2ZXSgd4VzfW1ic4ThdpZm\CCqdX3hckBDUiClZXzsd{BifCB{NTD1UUB1emWjdHXkJFIhcHK|IHLl[o9z\SCSRFfGJINp[WyuZX7n[UBjgSCrbX31co9jdG:2dHnu[y=> NUfGelQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3OlcxQDVpPkG2O|Y4ODh3PD;hQi=>
human BJ cells NGLTS4FHfW6ldHnvckBie3OjeR?= NGDiSWMzPSEQvF2= NGnPNVYzKGh? NF;KZWtKdmirYnn0bY9vKG:oIGDJN2she2mpbnHsbY5oKGmwIGDES2Yue3SrbYXsZZRm\CC|ZYL1cUB{fGG{dnXkJIh2dWGwIFLKJINmdGy|IITyZY5{\mWldHXkJJdqfGhicHzhd41q\CCHR1\QM3BJKGSxbXHpckBw\iCDa4SgZZN{\XO|ZXSgZZMhe3WycILld5Nqd25ib3[gVGguTUeIUDDy[YRqe3S{aXL1eIlwdiC2bzDwcIF{dWFibXXtZpJidmViYYSgNlUhfU1idILlZZRm\CB{IHjyd{Bj\W[xcnWgVGRITiClaHHscIVv\2ViYomgZ49v\m:lYXygcYlkem:|Y3;wfS=> M3n2RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{[3NFg2Lz5zNke2O|A5PTxxYU6=
mouse mast cells M1XmTGZ2dmO2aX;uJIF{e2G7 M1L4cVIxKM7:TR?= NFzQXVdKdmirYnn0bY9vKG:oIGPDSk1qdmS3Y3XkJHBMSi:Da4SgdIhwe3Cqb4L5cIF1cW:wIHnuJI1wfXOnIH3hd5Qh[2WubIOgZZQhOjBizszN M{XuWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{i5O|QzLz5zNke4PVc1OjxxYU6=
THP1 cells MYDGeY5kfGmxbjDhd5NigQ>? MmLyTY5pcWKrdHnvckBw\iCPQ2CxMYlv\HWlZXSgZ4hmdW:2YYjpd{Bw\iCWSGCxJINmdGy|LDDJR|UxRTN5IN88UU4> MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd6OUe0Nkc,OTZ5OEm3OFI9N2F-
mouse Raw264 macrophage NVPHOmptTnWwY4Tpc44h[XO|YYm= M{\McmlvcGmkaYTpc44hd2ZiQ{XhMY1m\GmjdHXkJHBMSi:Da4SgdIhwe3Cqb4L5cIF1cW:wIHnuJI1wfXOnIGLhe|I3PCCvYXPyc5Bp[WenLDDJR|UxRTFyIN88UU4> Ml;wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ5OEm3OFIoRjF4N{i5O|QzRC:jPh?=
THP1 cells NIf1cVNHfW6ldHnvckBie3OjeR?= MmPLTY5pcWKrdHnvckBw\iCPQ2CxMYlv\HWlZXSgVGtDN0GtdDDwbI9{eGixconsZZRqd25iaX6gWGhROSClZXzsd{whUUN3ME2xMlY2KM7:TT6= M2TVXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{i5O|QzLz5zNke4PVc1OjxxYU6=
THP1 cells Mn;5SpVv[3Srb36gZZN{[Xl? MYDJcohq[mm2aX;uJI9nKFOFRkGtbY5lfWOnZDDQT2IwSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDUTHAyKGOnbHzzMEBKSzVyPUGuNFEh|ryPLh?= M2jtW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{i5O|QzLz5zNke4PVc1OjxxYU6=
human A375 cells NVnpd212WHKxbHnm[ZJifGmxbjDhd5NigQ>? MkH0OFYhcA>? NXLhS4tGSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN|c2KGOnbHzzJIFnfGW{IES2JIhzeyxiSVO1NF05NjRizszNMi=> NXLx[IFHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUewOFkzPDhpPkG3NFQ6OjR6PD;hQi=>
HeLa cells NYH1OY0xTnWwY4Tpc44h[XO|YYm= M4[xNmlvcGmkaYTpc44hd2ZiQWitO|UxOyCkaX7kbY5oKHSxIILlZ49u[mmwYX70JHBtczNiZYjwdoV{e2WmIHnuJGhmVGFiY3XscJMh[nliV3XzeIVzdiCkbH;0MEBKSzV;MzFOwG0v M{nHcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUO1NlQ5Lz5zN{GzOVI1QDxxYU6=
human SW480 cells M33BSGZ2dmO2aX;uJIF{e2G7 MYeyNEDPxE1? MoX6NlQhcA>? NXnGZY0{TGWlcnXhd4UhcW5ic4Xyeol3cW5iZYjwdoV{e2mxbjDpckBpfW2jbjDTW|Q5OCClZXzsd{BifCB{MDD1UUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveEBidmGueYPpdy=> NVniUG1{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0O|I6PjJpPkG3OFczQTZ{PD;hQi=>
human A375 cells M2PidHBzd2yrZnXyZZRqd25iYYPzZZk> NUPv[Hl7UW6qaXLpeIlwdiCxZjDz[ZJ2dS2rbnT1Z4VlKHC{b3zp[oVz[XSrb36gc4YhcHWvYX6gRVM4PSClZXzsd{whUUN3ME24MlQh|ryPLh?= NEXSVJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[wNVc{QSd-MUe2NFE4Ozl:L3G+
human A2780 cells MVXBdI9xfG:|aYOgZZN{[Xl? MYSyJO69VQ>? MXOxNkBp Ml;iTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDjbZNxdGG2aX6tdoV{cXO2YX70JIh2dWGwIFGyO|gxKGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIIDoc5NxcG:{eXzheIVlKEGtdDDs[ZZmdCCjdDCyJJVOKGGodHXyJFEzKGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{Ng>? NG\xPFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[4OFAyQCd-MUe2PFQxOTh:L3G+
human H4 cells MmXWSpVv[3Srb36gZZN{[Xl? NIe3boszKGh? M4PXSmRm[3KnYYPlJIlvKE[\VlWtVmZRMyC4ZYPpZ4xmKGmwdHXud4l1gSCyZYKgZ4VtdCCrbjDoeY1idiCKNDDj[YxteyCjZoTldkAzKGi{czDy[YxifGm4ZTD0c{Bkd262cn;s Mn\JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyMkS1PFQoRjF6MEK0OVg1RC:jPh?=
Sf9 cells NXrNVVFqTnWwY4Tpc44h[XO|YYm= MYjJcohq[mm2aX;uJI9nKEONMjDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{NCCLQ{WwQVYvQSEQvF2u NGLwOJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOyNVcyPid-MUizNlE4OTZ:L3G+
rat RBL2H3 cells NX;RO4QxTnWwY4Tpc44h[XO|YYm= MnPrTY5pcWKrdHnvckBw\iCDMkOxPFcucW6mdXPl[EBl\We{YX71cIF1cW:wIHnuJJJifCCUQlyyTFMh[2WubIO= MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN{OEexOkc,OTh|Mki3NVY9N2F-
human U87MG cells MlvESpVv[3Srb36gZZN{[Xl? MkTMTY5pcWKrdHnvckBw\iCJU1uzMYJmfGFiaX6gbJVu[W5iVUi3UWch[2WubIOgZpkhTUyLU1GsJGlEPTB;OD6xJO69VS5? NVHCSIdHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizOFU3ODlpPkG4N|Q2PjB7PD;hQi=>
human H460 cells M2L5PWZ2dmO2aX;uJIF{e2G7 NUXQOWtIOzBizszN Mn\DTY5pcWKrdHnvckBw\iCSSUPLJIlvKGi3bXHuJGg1PjBiY3XscJMh[XO|ZYPz[YQh[XNiQXv0JJBpd3OyaH;yfYxifGmxbjDheEBU\XJiNEezJJVxKHSxIEOwJJVO Mn3uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3MEG2NFEoRjF6NUCxOlAyRC:jPh?=
human U251HRE cells MY\GeY5kfGmxbjDhd5NigQ>? NUHEOZhuUW6qaXLpeIlwdiCxZjDofZBwgGmjLXnu[JVk\WRiSFnGNUBi[3SrdnH0bY9vKGmwIHj1cYFvKFV{NUHIVmUh[2WubIOgZpkh[2WubDDiZZNm\CC{ZYDvdpRmeiCpZX7lJIF{e2G7 MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDVyMU[wNUc,OTh3MEG2NFE9N2F-
human 184B5 cells NYjNS3B1S3m2b4TvfIlkyqCjc4PhfS=> NUfMdVUxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hOTh2QkWgZ4VtdHNiYomgV3JDKGG|c3H5MEBIUTVyPUO5MlM4KM7:TT6= NEfqdXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
human MDA-MB-468 cells M3HJU2N6fG:2b4jpZ:Kh[XO|YYm= MlPmR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDifUBUWkJiYYPzZZktKEmFNUC9NVAvPCEQvF2u NVexemo6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MDA-MB-468 cells MmHwR5l1d3SxeHnjxsBie3OjeR?= M{W0SWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiMUCgeW0h[2iub4LvdZVqdmViYomgV3JDKGG|c3H5MEBIUTVyPUiuNkDPxE1w MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
MDA-MB-231 cells M1jVOmN6fG:2b4jpZ:Kh[XO|YYm= NFLDS4lEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NF03NjdzIN88UU4> Mn7JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
human MDA-MB-468 cells NFvHeZdEgXSxdH;4bYPDqGG|c3H5 Mn;SR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDpckBxemW|ZX7j[UBw\iB{MDD1UUBkcGyxcn;xeYlv\SCkeTDTVmIh[XO|YYpvwKwhUUN3ME20Mlc3KM7:TT6= NFixTIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
human MDA-MB-231 cells NGDhSllEgXSxdH;4bYPDqGG|c3H5 MnPYR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDpckBxemW|ZX7j[UBw\iBzMDD1UUBkcGyxcn;xeYlv\SCkeTDTVmIh[XO|YYmsJGdKPTB;ND6zOUDPxE1w NFuzS3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
human MDA-MB-231 cells MmfaR5l1d3SxeHnjxsBie3OjeR?= Mmr6R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDpckBxemW|ZX7j[UBw\iB{MDFOwG0h[2iub4LvdZVqdmViYomgV3JDKGG|c3H5MEBIUT1|LkOyJO69VS5? NX7W[mhORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MCF7 cells MX3DfZRwfG:6aXRCpIF{e2G7 MmLSR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BjgSCVUlKgZZN{[XluIFfJQVMvOTZizszNMi=> NE\FNFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
human MCF7 cells MVPDfZRwfG:6aXRCpIF{e2G7 MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEGwJJVOKGOqbH;yc5F2cW6nIHL5JHNTSiCjc4PhfUwhT0l3ME2zMlA5KM7:TT6= M2LpU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
human MCF7 cells NEPtOZpEgXSxdH;4bYPDqGG|c3H5 NIjLRnFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGmwIIDy[ZNmdmOnIH;mJFIxKM7:TTDjbIxwem:zdXnu[UBjgSCVUlKgZZN{[XluIFfJOVA:Oi54MzFOwG0v MnTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
Sf21 cells NGCwS3NHfW6ldHnvckBie3OjeR?= NFrLbZFKdmirYnn0bY9vKG:oIH3veZNmKHKnY3;tZolv[W62IGDJN2tidHCqYTDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiU3[yNUBk\WyuczygTWM2OD1yLkWg{txONg>? NHvSTY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe0PFI3QSd-MUm3OFgzPjl:L3G+
Sf9 cells NHzVe|BndHWxcnXzZ4VvfCCyb3zhdol7[XSrb36gZZN{[Xl? MX7Jcohq[mm2aX;uJI9nKGi3bXHuJHBKO0upYX3tZUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy|IHL5JIZtfW:{ZYPj[Y51KHCxbHHybZpifGmxbjDhd5NigQ>? NYfNcotCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxNlE3OzFpPkKxNVIyPjNzPD;hQi=>
Sf9 cells MmK0Sox2d3Knc3PlcpQheG:uYYLpfoF1cW:wIHHzd4F6 M3[3OGlvcGmkaYTpc44hd2ZiaIXtZY4hWEl|S3HsdIhiKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZpkh\my3b4Lld4NmdnRicH;sZZJqgmG2aX;uJIF{e2G7LDDJR|UxRTBwNUWg{txONg>? M164dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUKxOlMyLz5{MUGyNVY{OTxxYU6=
human IGROV1 cells MoTwSpVv[3Srb36gZZN{[Xl? MnXBNlQhcA>? MWfD[YxtKGO7Y3zlJIFzemW|dDDpckBpfW2jbjDJS3JQXjFiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNmKGG2IEWg[o9t\CCLQ{WwJIFnfGW{IEK0JIhzeyCkeTDmcI94KGO7dH;t[ZRzgQ>? NX;pVY1{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyNVYyPTFpPkKxNlE3OTVzPD;hQi=>
human IGROV1 cells MVnGeY5kfGmxbjDhd5NigQ>? MXKyOEBp NVThcIVZS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hUUeUT2[xJINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNUBxcGG|ZTDheEAyKG[xbHSgTWM2OCCjZoTldkAzPCCqcoOgZpkh\myxdzDjfZRwdWW2com= MnLJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MU[xOVEoRjJzMkG2NVUyRC:jPh?=
human IGROV1 cells NXfacVFITnWwY4Tpc44h[XO|YYm= MWKyOE81QCCq NVTCWJBpUW6qaXLpeIlwdiCxZjDQTVNMN0GtdDDpckBpfW2jbjDJS3JQXjFiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ5lkdGmwIFSxJIxmfmWuIHH0JFEhfG9iNTD0bY1meyCLQ{WwJIFnfGW{IEK0JJRwKDR6IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= M4\FTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkG2NVUyLz5{MUKxOlE2OTxxYU6=
human IGROV1 cells M1:4d2Z2dmO2aX;uJIF{e2G7 M3[2OFI1NzR6IHi= NXHs[|FJUW6qaXLpeIlwdiCxZjDQTVNMN0GtdDDpckBpfW2jbjDJS3JQXjFiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gdIhwe3Cqb4L5cIF1\WRiQVvUJIxmfmWuIHH0JFEhfG9iNTD0bY1meyCLQ{WwJIFnfGW{IEK0JJRwKDR6IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= NW\2bI5yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyNVYyPTFpPkKxNlE3OTVzPD;hQi=>
human HCT116 cells MYPDfZRwfG:6aXRCpIF{e2G7 M2XiOlczKGh? MoXDR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9OVYvODFizszNMi=> MlXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NEWyOVAoRjJzOUS1NlUxRC:jPh?=
human KB cells M2j6W2N6fG:2b4jpZ:Kh[XO|YYm= NV[5UnYxPzJiaB?= M4PYXmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtDKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NESuO|Yh|ryPLh?= MkTvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NEWyOVAoRjJzOUS1NlUxRC:jPh?=
HUVEC NInwVHNHfW6ldHnvckBie3OjeR?= NXfOU3oxOTBvMkWg{txO MV[zNEBucW5? MYTJcohq[mm2aX;uJI9nKFSQRnHsdIhiNXO2aX31cIF1\WRiaIXtZY4hUUODTT2xJJBzd22xdHXyJIFkfGm4aYT5JIV5eHKnc4Pl[EBqdiCKVW\FR{Bie3Onc4Pl[EBieyCkZYThMYdidGGldH;zbYRie2ViYXP0bZZqfHliYYSgNVAhfG9iMkWgeW0heHKndILlZZRm\CCob4KgN|AhdWmwczDi[YZwemViVF7GZYxxcGFiY3jhcIxmdmenIH3lZZN2emWmIHHmeIVzKDViaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeR?= MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB{NkSxNEc,OjJyMk[0NVA9N2F-
HUVEC NH7LcJJHfW6ldHnvckBie3OjeR?= MmX1NVAuOjVizszN M2n0ZlE3KGh? MV3Jcohq[mm2aX;uJI9nKFSQRnHsdIhiNXO2aX31cIF1\WRiSVPBUU0yKG2UTlGg[ZhxemW|c3nvckBqdiCKVW\FR{BifCBzMDD0c{AzPSC3TTDwdoV1emWjdHXkJIZweiBzNjDodpMh[mWob4LlJHRPTmGucHjhJINp[WyuZX7n[UBu\WG|dYLl[EBi\nSncjC2JIhzeyCkeTDSWE1RS1JiYX7hcJl{cXN? NH;2T2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkCyOlQyOCd-MkKwNlY1OTB:L3G+
human HCT116 cells NX3QSnZDTnWwY4Tpc44h[XO|YYm= MnHRNVAh|ryP M3jWO2lvcGmkaYTpc44hd2ZiQXv0JIV5eHKnc4Ppc44hcW5iaIXtZY4hUEOWMUG2JINmdGy|IHH0JFExKHWPIHL5JIludXWwb3Lsc5Qh[W6jbInzbZM> MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMkeyNUc,OjJ{MUK3NlE9N2F-
human HCT116 cells MnXTSpVv[3Srb36gZZN{[Xl? MnXuNVAh|ryP MYDJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCKMUC0O3IhdXW2YX70JIlvKGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEGtdDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGG2IEGwJJVOKGK7IHntcZVvd2Kub4SgZY5idHm|aYO= M2L2NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGyO|IyLz5{MkKxNlczOTxxYU6=
human HCT116 cells Mon3SpVv[3Srb36gZZN{[Xl? M1GwOVExKM7:TR?= MnPmTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiaX6gbJVu[W5iSFPUNVE3KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gRYt1KFOnckS3N{BxcG:|cHjvdplt[XSrb36gZZQhOTBidV2gZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>? NGeyTWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNlczOSd-MkKyNVI4OjF:L3G+
human HCT116 cells MoXqSpVv[3Srb36gZZN{[Xl? NX7lVWdwOTBizszN NEPYNoMyOCCvaX6= M4LPU2lvcGmkaYTpc44hd2ZiUFmzT4FteGijIFixNFQ4WiCvdYThcpQhcW5iaIXtZY4hUEOWMUG2JINmdGy|IIXzbY5oKFt|MmDdRXRRKGG2IEGwJJVOKGGodHXyJFExKG2rboO= NGnYWFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNlczOSd-MkKyNVI4OjF:L3G+
human HCT116 cells M2GwSWZ2dmO2aX;uJIF{e2G7 NEGxOmYyOCEQvF2= NXPWXFA6OTBibXnu MWTJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCrbjDoeY1idiCKQ2SxNVYh[2WubIOgeZNqdmdiW{OyVH1CXFBiYYSgNVAhfU1iYX\0[ZIhOTBibXnudy=> MnHnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUK3NlEoRjJ{MkGyO|IyRC:jPh?=
human HCT116 cells NEPHO|FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3zCNlQ5KGh? MoDES5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGNVOTF4IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJHBKO0ujbIDoZUBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPU[uO{DPxE1w NE[0ZZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNlczOSd-MkKyNVI4OjF:L3G+
human HCT116 cells NF30V2pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn7SOFghcA>? Moe1S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OU45KM7:TT6= MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMkeyNUc,OjJ{MUK3NlE9N2F-
human HCT116 cells MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVq0PEBp MoW2S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGNVOTF4IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJHBKO0ujbIDoZUBJOTB2N2KgcZV1[W62IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PS5|IN88US=> M{TsflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGyO|IyLz5{MkKxNlczOTxxYU6=
human A549 cells NX3QeGczS3m2b4TvfIlkyqCjc4PhfS=> MlPlO|IhcA>? MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYm= NGjKOow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4NFg2OSd-MkK0PFA5PTF:L3G+
human PC3 cells M2rDTGN6fG:2b4jpZ:Kh[XO|YYm= MVG3NkBp MkTvR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NkGuN|Uh|ryPLh?= MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR6MEi1NUc,OjJ2OEC4OVE9N2F-
human HL60 cells NFW0VI9EgXSxdH;4bYPDqGG|c3H5 NV\Nc|BFPzJiaB?= MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;OT65OEDPxE1w M{nPdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEiwPFUyLz5{MkS4NFg2OTxxYU6=
Sf21 cells NY\Y[ppRTnWwY4Tpc44h[XO|YYm= MmDzTY5pcWKrdHnvckBw\iCvb4Xz[UB4cWymIIT5dIUhWEl|S3HsdIhiKGW6cILld5Nm\CCrbjDT[lIyKGOnbHzzJINwNWW6cILld5NqdmdiTj30[ZJucW6jbDDIbZMufGGpZ3XkJIh2dWGwIIC4OYEhfXOrbnegUE1idHCqYT3wbI9{eGijdHnkfYxqdm:|aYTvcEB{fWK|dILheIUh[nliVFzDJIJie2WmIIDoc5NxcG:{IHntZYdqdmduIFnDOVA:OC53IN88US=> Mnv1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3MkC2N|AoRjJ{NUKwOlMxRC:jPh?=
HEK293 cells Ml3MSpVv[3Srb36gZZN{[Xl? M4nPR|EvPSCq NUTFcWdPTGm|cHzhZ4Vu\W62IH;mJHs{UF2OU1Sg[pJwdSCqdX3hckA2UFR4IILlZ4VxfG:{IHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYX\0[ZIhOS53IHjyd{BjgSCuaYH1bYQhe2OrboTpcIxifGmxbjDjc5VvfGmwZx?= NEHofFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWzO|E2Oyd-MkK1N|cyPTN:L3G+
human H1299 cells NGjWeVRHfW6ldHnvckBie3OjeR?= MXOwMlEuOzBizszN M3jkT|I1KGh? MmjjTY5lfWO2aX;uJI9nKEqQSz3t[YRq[XSnZDDDTG9RKGW6cILld5Nqd25iaX6gbJVu[W5iSEGyPVkh[2WubIOgZZQhOC5zIITvJFMxKHWPIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= NXXmXIVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2NlIxPjlpPkKyOlIzODZ7PD;hQi=>
human H1299 cells NHzjfZdHfW6ldHnvckBie3OjeR?= NU\aSlh7OC5zLUOwJO69VQ>? NFO3[XgzPCCq MoXtTY5lfWO2aX;uJI9nKESUNTDlfJBz\XO|aX;uJIlvKGi3bXHuJGgyOjl7IHPlcIx{KGG2IECuNUB1dyB|MDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ{MkC2PUc,OjJ4MkKwOlk9N2F-
human H1299 cells M1vOcmZ2dmO2aX;uJIF{e2G7 MYWwMlEuOzBizszN NYLTcm9sOjRiaB?= NWDJTXZlTG:5bjDy[Yd2dGG2aX;uJI9nKGOLQWCyJIV5eHKnc4Ppc44hcW5iaIXtZY4hUDF{OUmgZ4VtdHNiYYSgNE4yKHSxIEOwJJVOKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXNiaX6gdJJme2WwY3Wgc4YhOTByIIXnM41tKFSUQVnMJIFv\CCSSUPLJIlvcGmkaYTvdkBNYTJ7NECwNi=> MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ{MkC2PUc,OjJ4MkKwOlk9N2F-
human H1299 cells Mor3SpVv[3Srb36gZZN{[Xl? MmLQNE4yNTNyIN88US=> MYeyOEBp MVnEc5dvKHKnZ4XsZZRqd25ib3[gZ2lCWDJiZYjwdoV{e2mxbjDpckBpfW2jbjDINVI6QSClZXzsd{BifCByLkGgeI8hOzBidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ{MkC2PUc,OjJ4MkKwOlk9N2F-
MDA-MB-231 cells MXPD[YxtKGmwdnHzbY9vKGG|c3H5 Mmn6NlQhcA>? MWTJcohq[mm2aX;uJI9nKGWyaYTo[Yxq[WxiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJINmdGxibXnndoF1cW:wIH;mJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNicILlMYlv[3WkYYTl[EBnd3JiMkSgbJJ{KGK7IHPlcIwhcW64YYPpc44h[XO|YYmsJGlEPTB;MD6zPEDPxE1w MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjhyNEGwPEc,OjJ6MESxNFg9N2F-
human LNCAP cells M3m3S2Z2dmO2aX;uJIF{e2G7 MYCwMlEuOzBizszN MWCyOEBp M2\CSWRwf26{ZXf1cIF1cW:wIH;mJJN2en[rdnnuJIV5eHKnc4Ppc44hcW5iaIXtZY4hVE6FQWCgZ4VtdHNiYYSgNE4yKHSxIEOwJJVOKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh|MkOxOkc,OjJ6M{KzNVY9N2F-
human LNCAP cells M4PjUWZ2dmO2aX;uJIF{e2G7 MmjDNE4yNTNyIN88US=> MkmwN|AhdWmw NHj6R5hKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gUG5ESVBiY3XscJMh[XRiMD6xJJRwKDNyIIXNJIFnfGW{IEOwJI1qdnNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ MnvkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6M{KzNVYoRjJ{OEOyN|E3RC:jPh?=
human PC3 cells M2Gzb2Z2dmO2aX;uJIF{e2G7 Mlm5OVAh|ryP NE[zd3g5KGh? MoqzTY5lfWO2aX;uJI9nKHB{MTDwdo91\WmwIHX4dJJme3Orb36gbY4hcHWvYX6gVGM{KGOnbHzzJIF1KDVyIIXNJIlv[3WkYYTl[EBnd3JiODDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yC{ZXzheIl3\SC2bzD1cpRz\WG2ZXSgZ49vfHKxbB?= M4fXWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUm4OFczLz5{Mkm5PFQ4OjxxYU6=
human BT474 cell M3PNRXBzd2yrZnXyZZRqd25iYYPzZZk> M{jqdVczKGh? MkXQTY5pcWKrdHnvckBw\iCqdX3hckBDXDR5NDDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IIPw[YN1em:yaH;0c41mfHKrYzDhcoFtgXOrc,-8kEBKSzVyPUKwMlch|ryPLh?= MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzMECwOUc,OjN2MUCwNFU9N2F-
human PC3 cell M3f3d3Bzd2yrZnXyZZRqd25iYYPzZZk> MmLqO|IhcA>? MX3Jcohq[mm2aX;uJI9nKGi3bXHuJHBEOyClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KHOyZXP0do9xcG:2b33leJJq[yCjbnHsfZNqeyxiSVO1NF0yOi5zIN88UU4> M3K3cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEGwNFA2Lz5{M{SxNFAxPTxxYU6=
human PC3 cells NXrN[4M5TnWwY4Tpc44h[XO|YYm= NUSzNmlVOzBibXnu NF\RNVVKdmirYnn0bY9vKG:oIGDJN2shcW5iaIXtZY4hWEN|IHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJGFMXCCyaH;zdIhwenmuYYTpc44h[XRic3XybY5mKDR5MzDh[pRmeiB|MDDtbY5{KGK7IFXMTXNCNCCLQ{WwQVEvO87:TT6= NWnFUJdVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVAxODVpPkKzOFExODB3PD;hQi=>
human MGC803 cells MUDGeY5kfGmxbjDhd5NigQ>? MmG0NlUh|ryP M3;4[lQ5KGh? M2PPeGNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJG1ISzhyMzDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG|ZTDheEAzPSC3TTDh[pRmeiB2ODDodpMhfXOrbnegdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDh[pRmeiB2ODDodpMh[nliZnzve{BkgXSxbXX0[ZIhemWuYYTpeoUhfG9iY3;ueJJwdA>? NW\GdJlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNVk5PjlpPkK0NVE6QDZ7PD;hQi=>
mouse RAW264.7 cells NF3JN4JHfW6ldHnvckBie3OjeR?= M2HQOFI2KM7:TR?= M1HpZlIxKGh? MWfJcohq[mm2aX;uJI9nKFCLM1uvRWtVKGmwIH3veZNmKFKDV{K2OE44KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gUHBUNWmwZIXj[YQhcU6RUzDwdo91\WmwIHX4dJJme3Orb36gZZQhOjVizszNJIFnfGW{IEKwJIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> NU\VfnpNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVk3OTZpPkK0Nlk6PjF4PD;hQi=>
human A549 cells M{PyeXBzd2yrZnXyZZRqd25iYYPzZZk> NGLxOIQ4OiCq MkTyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDNUS5JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYXLzc5Jj[W6lZTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTh{LkOyJO69VS5? Mm\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OUO3PFcoRjJ3NkmzO|g4RC:jPh?=
human HuH7 cells M2rZc3Bzd2yrZnXyZZRqd25iYYPzZZk> M2DYZVczKGh? MoPtRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKdVi3JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYXLzc5Jj[W6lZTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTZ5LkG4JO69VS5? M3;FelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkmzO|g4Lz5{NU[5N|c5PzxxYU6=
human HCT116 cells NHvlXpBRem:uaX\ldoF1cW:wIHHzd4F6 NFLhUJk4OiCq MnTiRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhZpNwemKjbnPlJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NUGuPFIh|ryPLh?= MnHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OUO3PFcoRjJ3NkmzO|g4RC:jPh?=
human HL60 cells MXPQdo9tcW[ncnH0bY9vKGG|c3H5 NGmzfpA4OiCq M4XKNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zOD60N{DPxE1w MlPsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OUO3PFcoRjJ3NkmzO|g4RC:jPh?=
Sf9 cells NGPvWHpHfW6ldHnvckBie3OjeR?= M1TKPGlvcGmkaYTpc44hd2ZiSHnzMZRi\2enZDDoeY1idiCFS{Kg[ZhxemW|c3XkJIlvKFOoOTDj[YxteyxiSVO1NEA:KDZwOTFOwG0v M4TydVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyOUm4N|UyLz5zMEm5PFM2OTxxYU6=
HeLa cells NHK2W41HfW6ldHnvckBie3OjeR?= MmjkTY4hfmm2cn:gbY5pcWKrdHnvckBw\iCGTlGt[IVx\W6mZX70JJBzd3SnaX6gb4lv[XOnKFTORU1RUyliZoLvcUBJ\UyjIDjoeY1idiClYYLjbY5wdWFrIHPlcIx{NixiSVO1NEA:KDFwNDFOwG0v M1nTdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{OUSxN|M6Lz5zMkm0NVM{QTxxYU6=
HeLa cells M3T3[mZ2dmO2aX;uJIF{e2G7 NGPjVZJKdmirYnn0bY9vKG:oIFTORUBl\XCnbnTlcpQheHKxdHXpckBscW6jc3WgbZNwdGG2ZXSg[pJwdSCKZVzhJINmdGy|LDDJR|UxKD1iMT61JO69VS5? MnrxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV4NUi4O|AoRjF3NkW4PFcxRC:jPh?=
Sf21 cells M3j5Z2Z2dmO2aX;uJIF{e2G7 NWm1enNXUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNM[mW2YTDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiU3[yNUBk\WyuczygTWM2OCB;IECuPUDPxE1w NUnWT5ZZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFgzPjlpPkG5O|Q5OjZ7PD;hQi=>
Sf21 cells NEP5cVFHfW6ldHnvckBie3OjeR?= NUHxd5hiUW6qaXLpeIlwdiCxZjDic5ZqdmVicnXjc41jcW6jboSgVGk{U2ejbX3hJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3cz3pcoZm[3SnZDDT[lIyKGOnbHzzMEBKSzVyIE2gO{DPxE1w NWLEOlNDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFgzPjlpPkG5O|Q5OjZ7PD;hQi=>
HeLa cells MmrjSpVv[3Srb36gZZN{[Xl? Mkf1RYN1cX[rdImgZZQhWEl|SzDpckBpfW2jbjDI[WxiKGOnbHzzJIJ6KEWOSWPBMEBGSzVyIE2gNU42KM7:TT6= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB7MkOyN{c,OjByOUKzNlM9N2F-
Sf21 cells MYrGeY5kfGmxbjDhd5NigQ>? MWnJcohq[mm2aX;uJI9nKFCLM1vk[Yx1[SCneIDy[ZN{\WRiaX6gZ4VtdHNiY3:t[ZhxemW|c3nu[{BPNXSncn3pcoFtKEircz30ZYdo\WRiaIXtZY4heDh3YTD1d4lv\yCOLXHsdIhiNXCqb4PwbIF1cWS7bHnuc5NqfG:uIIP1ZpN1emG2ZTDifUBVVENiYnHz[YQheGixc4Doc5IhcW2jZ3nu[{whUUN3MDC9JFAvPTdizszNMi=> MlzqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3MkC2N|AoRjJ{NUKwOlMxRC:jPh?=
Sf21 cells MlrvSpVv[3Srb36gZZN{[Xl? NH35U2FKdmirYnn0bY9vKG:oIHj1cYFvKHerbHSgeJlx\SCSSUPLZoV1[SCneIDy[ZN{\WRiaX6gV4YzOSClZXzsd{Bkdy2neIDy[ZN{cW6pIF6teIVzdWmwYXygTIl{NXSjZ3fl[EBpfW2jbjDwPFViKHW|aX7nJGwu[WyyaHGtdIhwe3CqYYTp[JltcW6xc3n0c4whe3Wkc4TyZZRmKGK7IGTMR{Bj[XOnZDDwbI9{eGixcjDpcYFocW6pLDDJR|UxKD1iMD65O{DPxE1w M3vzflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUKwOlMxLz5{MkWyNFY{ODxxYU6=
HL60 cells M{j3emFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NHTSUVg{KGSjeYO= MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOyCmYYnzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDF2IN88UU4> MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl2NUGxNEc,OjZ7NEWxNVA9N2F-
U937 cells NVXKUXFUSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MnuyN{Bl[Xm| M3nzPWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUmzO{Bk\WyuczDt[YF{fXKnZDDh[pRmeiB|IHThfZMh[nliTWTTJIF{e2G7LDDJR|UxKD1iMUSg{txONg>? NGrBflU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm0OVEyOCd-Mk[5OFUyOTB:L3G+
Jurkat cells NIjTdmNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NIXxUII{KGSjeYO= M1G4fWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSoXyb4F1KGOnbHzzJI1m[XO3cnXkJIFnfGW{IEOg[IF6eyCkeTDNWHMh[XO|YYmsJGlEPTBiPTCyNkDPxE1w MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl2NUGxNEc,OjZ7NEWxNVA9N2F-
K562 cells M1WxS2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 MoDMN{Bl[Xm| NYHl[I0{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJI1m[XO3cnXkJIFnfGW{IEOg[IF6eyCkeTDNWHMh[XO|YYmsJGlEPTBiPTCzPEDPxE1w M2XBUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUS1NVExLz5{Nkm0OVEyODxxYU6=
U266 cells NXrvNmF{SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MUCzJIRigXN? M3rDOGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUK2OkBk\WyuczDt[YF{fXKnZDDh[pRmeiB|IHThfZMh[nliTWTTJIF{e2G7LDDJR|UxKD1iNE[g{txONg>? MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl2NUGxNEc,OjZ7NEWxNVA9N2F-
MDA-MB-231 cells MVrBcpRqdWmpcnH0c5J6KGG|c3H5 MlHrNlQhcHK| NWHXeGhzSW62aX3p[5JifG:{eTDhZ5Rqfmm2eTDh[4FqdnO2IFXHSkBqdmS3Y3XkJINp\W2xdHH4bZMhcW5iaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BxemWrbnP1ZoF1\WRiZn;yJFI1KGi{czDmc4xtd3enZDDifUBGT0ZiYXTkbZRqd25iZn;yJFMvPSCqcoOgZpkhdGmpaISgcYlkem:|Y3;wfUwhUUN3MDC9JFAvOzhizszNMi=> MlzGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3OUiyN|coRjJ5NUm4NlM4RC:jPh?=
MDA-MB-231 cells NIXrdWtCdnSraX72ZZNqfmViYYPzZZk> NVzUUZpjOy53IHjydy=> MVXBcpRqcW64YYPpeoUh[WO2aY\peJkhcW5iaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGVITi2rbnT1Z4VlKGOnbHygbY53[XOrb36gZYZ1\XJiMz61JIhzeyxiSVO1NEA:KDBwM{ig{txONg>? NI\D[|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OECwPVUzOSd-MkiwNFk2OjF:L3G+
HEK293T cells MV;GeY5kfGmxbjDhd5NigQ>? MonJNUBpeg>? NYPtV5lQUW6qaXLpeIlwdiCxZjDpcY1w[mmuaYrl[EBPNUy\Mkm0NFAzKGKnYXSgZolv\GmwZzD0c{BRUTONYnX0ZUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCKRVuyPVNVKGOnbHzzJIlv[3WkYYTl[EBnd3JiMTDodkBjgSCOQz3NV{9OWyCjbnHsfZNqeyxiSVO1NEA:KDBwNEKg{txONg>? MlXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OECyOlEoRjJ6MkiwNlYyRC:jPh?=
HEK293T cells MnnJSpVv[3Srb36gZZN{[Xl? MoC3NUBpeg>? NGP3fHRKdmirYnn0bY9vKG:oIHntcY9jcWyrenXkJG4uVFl{OUSwNFIh[mWjZDDibY5lcW6pIITvJHBKO0umZXz0ZUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCKRVuyPVNVKGOnbHzzJIlv[3WkYYTl[EBnd3JiMTDodkBjgSCOQz3NV{9OWyCjbnHsfZNqeyxiSVO1NEA:KDFwNUOg{txONg>? NEfZZVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NFI3OSd-MkiyPFAzPjF:L3G+
HEK293T cells M1TuSmZ2dmO2aX;uJIF{e2G7 M{fwVVEhcHJ? M1fIZ2lvcGmkaYTpc44hd2ZiaX3tc4JqdGm8ZXSgUk1NYTJ7NECwNkBj\WGmIHLpcoRqdmdidH:gVGk{U2GucHjhJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKEiHS{K5N3Qh[2WubIOgbY5kfWKjdHXkJIZweiBzIHjyJIJ6KEyFLV3TM21UKGGwYXz5d4l{NCCLQ{WwJF0hOi5|NzFOwG0v MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MEK2NUc,Ojh{OECyOlE9N2F-
MDA-MB-231 cells M2fmSWZ2dmO2aX;uJIF{e2G7 MmHvTY5pcWKrdHnvckBw\iCHR1[tbY5lfWOnZDDpcpZie2mxbjDv[kBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOzhizszNMi=> NE\Oe249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOwNlQxOSd-MkizNFI1ODF:L3G+
MCF7 cells NXHkPY1ETnWwY4Tpc44h[XO|YYm= MXmxNEB2VQ>? M2rleVEhcHJ? MWrJcohq[mm2aX;uJI9nKEmJRkHSJJBpd3OyaH;yfYxifGmxbjDheEBVgXJzMU[xJJJme2mmdXWgbY4hcHWvYX6gUWNHPyClZXzsd{BifCBzMDD1UUBi\nSncjCxJIhzKGK7IFjv[YNpe3RiM{OyOVghe3SjaX7pcoch[mG|ZXSgbY1ufW6xaHnzeI9kcGWvaXPhcEBidmGueYPpdy=> MoCwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NUe0N|AoRjJ6NUW3OFMxRC:jPh?=
SKOV3 cells M{jPWmZ2dmO2aX;uJIF{e2G7 MoPWNlAhfU1? MkjyNlQhcHK| NEDubGNKdmirYnn0bY9vKG:oIFLEUmYucW6mdXPl[EBqdn[jc3nvckBqdiCqdX3hckBUU0:YMzDj[YxteyCjdDCyNEB2VSCjZoTldkAzPCCqcoOgbY4h[nlibXH0dolo\WxiaX72ZZNqd25iYYPzZZk> M{m5PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUKyOFg1Lz5{OUGyNlQ5PDxxYU6=
SKOV3 cells NFTVW3RCdnSrbXnndoF1d3K7IHHzd4F6 NX7vNY9EOjBidV2= MkPNNlQhcHK| NWryO2RMSW62aX3p[5JifG:{eTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONT2[zJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiQlTOSk1qdmS3Y3XkJINmdGxibXnndoF1cW:wIHH0JFIxKHWPIHHmeIVzKDJ2IHjyd{BjgSC|Y4LheINpKHexdX7kJIhm[WyrbnegZZN{[Xl? NVTPe|dGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxNlI1QDRpPkK5NVIzPDh2PD;hQi=>
NB1643 cells MYLxTHRUKGG|c3H5 MojPdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?= NULEb5pwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 cells Moq1dWhVWyCjc4PhfS=> NUW2SI14eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> NFTrb4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 cells NU\OSmZveUiWUzDhd5NigQ>? MofKdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= MmHRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC cells NEPZN4lyUFSVIHHzd4F6 MonhdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= M1;V[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
J774 cells MUXBcpRqcW6obHHtcYF1d3K7IHHzd4F6 M37HSFI1KGi{cx?= NWj0[JRWSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBLPzd2IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBNWFNvaX7keYNm\CCPQ2CxJIV5eHKnc4Ppc44h[W[2ZYKgNlQhcHK|IHL5JGVNUVODLDDJR|UxKD1iMz63JO69VS5? NUnmdIlKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3NlY3QDBpPkK5O|I3PjhyPD;hQi=>
J774 cells MW\BcpRqcW6obHHtcYF1d3K7IHHzd4F6 MonYNlQhcHK| NIrFSpZCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJGo4PzRiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGxRWy2rbnT1Z4VlKEmONjDlfJBz\XO|aX;uJIFnfGW{IEK0JIhzeyCkeTDFUGlUSSxiSVO1NEA:KDVwMTFOwG0v M{P2eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{K2OlgxLz5{OUeyOlY5ODxxYU6=
J774 cells NXz0XFNpSW62aXnu[oxidW2jdH;yfUBie3OjeR?= NE[5VmozPCCqcoO= M{LWPWFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hdW:3c3WgTlc4PCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gUHBUNWmwZIXj[YQhdmm2cnnjJI95cWSnIIDyc4R2[3Srb36gZYZ1\XJiMkSgbJJ{KGK7IFfybYV{eyCjc4PhfUwhUUN3MDC9JFgvQSEQvF2u M1j4PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{K2OlgxLz5{OUeyOlY5ODxxYU6=
J774 cells MV3GeY5kfGmxbjDhd5NigQ>? MoX6NVAhfU1? MnKzOEBpenN? NYfqT2x{UW6qaXLpeIlwdiCxZjDQTVNMN0GtdDDpckBud3W|ZTDKO|c1KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDMVHMucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9vKGG2IGPldlQ4OyCjdDCxNEB2VSCjZoTldkA1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MoDOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5Mk[2PFAoRjJ7N{K2OlgxRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
E-cadherin / p-Akt / Akt; 

PubMed: 29731993     


Immunoblot analysis of E-cadherin, P-AKT, and AKT in SNU-C5/5-FU cells treated with LY294002 (20 μM).

beta-catenin / p-GSK3β / Cyclin D1; 

PubMed: 29731993     


Immunoblot analysis of P-AKT, AKT, β-catenin, P-GSK-3β, GSK-3β, and cyclin D1 in SNU-C5/5-FU cells treated with LY294002 (20 μM).

Bcl-xl / Bax / caspase3 / cleaved caspase-3; 

PubMed: 25344912     


Four esophageal cancer cell lines were treated with different concentrations of LY294002 for 48 h, and cell lysates were collected for Western blot analysis of p-AKT, AKT, p-GSK3β, GSK3β, Bcl-xL, Bax, caspase-3, and cleaved caspase-3.

p-p70S6K (T389) / p-GSK3β(S9) / pERK / Vinculin; 

PubMed: 23251002     


HT29, Colo205, and RKO cells were treated for 2 h with PLX4720, LY294002 or their combination at indicated concentrations. Cell lysates were subjected to western blot analysis with antibodies against phosphorylated or total forms of AKT or ERK1/2, and antibodies against p-P70S6K, pGSK3β or vinculin.

pPKB-S473; 

PubMed: 20649566     


Typical Western blot showing that basal pPKB-S473 was reduced by increasing concentrations of LY294002 (upper panel). Pre-incubating 10 µM of the MEK-1/2 inhibitor U0126 induced pPKB–S473 levels which were reduced when rising concentrations of LY294002 were added. A full suppression of pPKB–S473 below the detection limit was seen at 30 µM PI3K inhibitor (10 µM U0126 + 30 µM LY294002). β-Actin immunoreaction served as loading control.

29731993 25344912 23251002 20649566
Growth inhibition assay
Cell viability; 

PubMed: 25344912     


MTT assay was used to determine the effects of different concentrations of LY294002 on viability of esophageal cancer cells lines KYSE150, HKESC-1, KYSE270, and T.Tn. Bars, SD; * P < 0.05; **, P < 0.01; ***, P < 0.001 compared with DMSO-treated cells.

25344912
Immunofluorescence
α-SMA / CD31; 

PubMed: 27671604     


Immunofluorescence analysis for the expression levels of CD31 and α-SMA in Control, LY294002, As2O3 and As2O3 + LY294002 groups. Scale bar = 30 μm. (in HAECs).

E-cadherin / beta-catenin; 

PubMed: 29731993     


The localization of E-cadherin and β-catenin were confirmed by confocal microscopy. Scale bars, 20 μm.

COX-2 / p-NFκB; 

PubMed: 29731993     


The localization of Cox-2 and P-NF-κB was confirmed by confocal microscopy. Scale bars, 20 μm.

FOXO3a; 

PubMed: 18388194     


C2C12 cells were plated into two-well chamber sliders for 24 h and then treated with 20 μm LY294002 or the same amount of vehicle (ethanol) for 16 h. Cells were fixed and FOXO3a was stained. LY294002 treatment activates FOXO3a and leads its translocation into the nucleus.

27671604 29731993 18388194
ELISA
IL-10 / IL-1β / TNFα / IL-6; 

PubMed: 22208359     


Microglial cells were pre-treated with LY294002 for 1 h and then stimulated with LPS (100 ng/ml) or PIC (10 μg/ml) for 16 h. ELISA were performed. All values were normalized to those obtained in cultures stimulated with LPS or PIC without LY294002 (= 1). At least 3 cases were analyzed for each experiment, and statistics were performed using t-test comparing values with vs. without LY294002.

22208359
In vivo

LY294002 also results in suppression of tumor growth and induction of apoptosis, especially in the LoVo tumors, and therefore shows remarkable effectiveness in the mouse peritonitis carcinomatosa model. [2] LY294002 significantly inhibits growth and ascites formation of ovarian carcinoma. [3]

Protocol

Kinase Assay:

[4]

- Collapse

kinase assays:

PI3K inhibition by LY294002 is determined in a radiometric assay using purified, recombinant enzymes with 1 μM ATP. The kinase reaction is carried out for 1 hour at room temperature (24oC) and is terminated by addition of PBS. IC50 values are subsequently determined using a sigmoidal dose–response curve fit (variable slope). CK2 and GSK3β (glycogen synthase kinase 3β) inhibition is established by kinase selectivity screening. LY294002 is tested against the Upstate panel of kinases in 10 μM ATP.
Cell Research:

[2]

- Collapse
  • Cell lines: Colon cancer cell lines DLD-1, LoVo, HCT15, and Colo205
  • Concentrations: 0–50 μM
  • Incubation Time: 0–48 hours
  • Method:

    1.0×105 cells (100 μL volume/well) are inoculated into 96-well microtiter plates. LY294002 is added to triplicate wells and cultured at 37oC for 0–48 hours. After treatment, 10 μL of Premix WST-1 are added to each microculture well, and the plates are incubated for 60 minutes at 37oC, after which absorbance at 450 nm is measured with a microplate reader.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: Two groups of athymic nude mice (5–7 weeks) are inoculated i.p. with OVCAR-3 cells
  • Dosages: 0–100 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 36 mg/mL (117.13 mM)
Ethanol 21 mg/mL (68.32 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+ 40%PEG 300+5% Tween 80+50%ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 307.34
Formula

C19H17NO3

CAS No. 154447-36-6
Storage powder
in solvent
Synonyms SF 1101, NSC 697286
Smiles C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02337309 Terminated Drug: SF1126 Neuroblastoma New Approaches to Neuroblastoma Therapy Consortium|SignalRX Pharmaceuticals Inc.|University of Southern California July 9 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to buy a inhibitor that can inactivates Akt/PI3K. I notice the protocol of LY294002 (catalog no. s1105) says it will inactivates Akt/PKB. Is LY294002 available for Akt/PI3K inhibition?

  • Answer:

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively. It can inhibit PI3K/AKT. PKB is the alternative name of AKT.

  • Question 2:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • Answer:

    It can be dissolved in 4% DMSO/30% PEG 300/5% Tween 80/ddH2O at 5 mg/ml clearly, and the concentration of DMSO is safe for in vivo experiments.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy LY294002 | LY294002 supplier | purchase LY294002 | LY294002 cost | LY294002 manufacturer | order LY294002 | LY294002 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID